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ABSTRACT 
Drug metabolism can produce metabolites with physicochemical and 
pharmacological properties that differ significantly from those of the parent drug. 
These mechanisms are an important factor in the high attrition rates currently found in 
drug discovery and development, including late-stage clinical trials. The relevance of 
drug metabolism for both safety and efficacy implies a vital requirement for efficient 
and reliable ways to predict drug metabolism in vitro, in silico, and in intact 
organisms. In this Perspective, we provide an overview of the state-of-the-art of 
experimental and computational approaches for investigating drug metabolism. We 
highlight the scope and limitations of these methods and indicate strategies to harvest 
the synergies resulting from combining measurement and prediction. 
INTRODUCTION 
Metabolism is a signature of living systems, and enables organisms to create a 
viable environment within which to perform the complex biochemical transformations 
that maintain homeostasis. The metabolic system has evolved as the main line of 
defence against foreign, hazardous substances, by transforming them into readily 
excretable metabolites. These xenobiotics also include synthetic drugs, in addition to 
naturally occurring substances (e.g. bacterial, fungal and herbal toxins), often 
produced as part of a specific defence mechanism. Recent studies have highlighted 
the often synergistic signalling between the host organism and the microbiome 
facilitated by metabolism
1
. For about 75% of all drugs metabolism is one of the major 
clearance pathways
2,3
. The process of biotransformation can produce metabolites with 
substantially altered physicochemical, physiological, pharmacological, and 
toxicological profiles
4-6
. Metabolism is the main factor mediating the activation, 
deactivation, toxification and detoxification of small molecules, and is a key 
determinant in the performance and safety of small molecules, including their uses in 
medicines, cosmetics, nutritional supplements and agrochemicals (Box 1). 
 
<<Box 1 approx. here>> 
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The complexity and malleability of the metabolic system cannot be overstated, 
A plethora of diverse enzyme families are involved in xenobiotic metabolism, 
including cytochrome P450s (CYPs), dehydrogenases, flavin-containing 
monooxygenases, hydrolases, peroxidases, UDP-glucuronosyltransferases, 
sulfotransferases, and glutathione S-transferases
7
. Their expression patterns and 
substrate specificities can vary greatly among different species, which implies there is 
a risk of missing toxic metabolites formed in humans when extrapolating from in vitro 
and animal testing results. Expression patterns also differ between tissues and organs, 
and there are indications that metabolic enzymes engage in synergistic collaborations 
with transporters (e.g. CYP 3A4 and P-glycoprotein
8,9
). On top of this, many inter- 
and intra-individual factors need to be considered, such as gender differences and 
genetic polymorphisms, age, biological rhythms, pregnancy, intestinal flora, diseases, 
stress, lifestyle, diet and medication
4
. Hence even with the advanced technologies and 
knowledge available today, accurate prediction remains highly challenging. 
Understanding metabolic processes on a molecular level of detail is of 
fundamental importance and key to successful drug discovery and development. 
Knowing the metabolic properties of a molecule can help to optimize the stability and 
in consequence the in vivo half-life and risk-benefit ratio of a drug. A plethora of 
experimental methods are available for investigating the metabolic fate of drugs at an 
unprecedented level of detail. However, these experimental approaches remain 
demanding with respect to scientific equipment, human expertise, cost and time, 
which have acted as major drivers for the development of computational tools for 
drug metabolism prediction. In silico methods allow the prediction of the metabolic 
fate of virtual compounds and to plan for the most promising strategy to optimize 
metabolic stability of project compounds a priori. 
Experimental and theoretical approaches are (still) all too often regarded as 
separate domains. It is most important to realize that there is enormous potential for 
synergy in the combination of both areas, which will allow the analysis and prediction 
of drug metabolism to make a major leap forward. 
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BIOSYSTEMS AND ANALYTICAL METHODS FOR 
INVESTIGATING DRUG METABOLISM 
CYPs are of major significance to drug metabolism, and the most relevant 
forms are expressed predominantly in the liver, but also in a whole variety of other 
organs at lower expression levels (Figure 1). Hence liver, or liver-derived in vitro 
systems are often the most convenient, interesting and important experimental model 
systems for metabolism studies, e.g. when considering the first-pass metabolism of an 
orally bioavailable drug. Because of the considerable variability in metabolism among 
different species it is essential and valuable early in drug discovery to use in vitro 
systems with human-derived material, since man is generally the target species. 
Several in vitro systems, as well as new in vivo approaches are available and can be 
specifically used depending on the issue or problem to be solved (Table 1). The 
simplest systems are recombinant enzymes (expressed together with coenzymes to 
achieve optimal catalytic activity). They can be used e.g. as a single CYP isoform 
system to assess which isoforms are involved in the metabolism of a compound or for 
drug interaction studies. From native material, e.g. liver, different enzyme families 
can be separated by centrifugation. Soluble cytosolic enzymes, e.g. sulfotransferases 
(SULTs) remain in the supernatant, whereas membrane-bound enzymes like CYPs, 
UDP-glucuronosyltransferases (UGTs) etc. are enriched in the pellet and after re-
suspension, the material described as “microsomes” (membrane vesicles of the 
endoplasmic reticulum) are obtained. Microsomal preparations can be easily stored 
while retaining their functionality, and are convenient to use because they are also 
available in sufficient quantity for high throughput assays. 
 
<< Figure 1 approx. here>> 
<< Table 1 approx. here>> 
 
Another subcellular matrix is the S9-fraction, which consists of both the 
cytosolic and microsomal fractions. In all subcellular fractions, due to dilution or 
washout of cofactors during the preparation process, cofactor-dependent enzymes in 
microsomes, e.g. CYPs or UGTs need to be specifically supplemented with the 
cofactor (NADPH in the case of CYPs) to regain enzymatic activity. The 
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metabolically most competent system is one having intact liver cells (hepatocytes), 
with all appropriate cofactors, coenzymes etc. present in physiological conditions and 
environment. Hepatocytes, while being less “robust” than microsomes, are useful 
when a more comprehensive picture of the hepatic metabolism of a selected 
compound is required. Both fresh and commercially produced cryopreserved primary 
hepatocytes, or immortalized hepatocyte-derived cell lines can be easily produced 
from preclinical species, and there is now more straightforward access to human 
derived material. New preclinical models such as “humanized mice” (either mice with 
specific human drug-metabolising genes inserted
10
 or chimeric animals where human 
hepatocytes have replaced >90% of the murine hepatocytes in the liver
11
) are 
becoming available which may improve studies of human metabolism, drug-drug 
interactions etc. in an in vivo animal model very early in drug discovery or 
development, significantly before entering clinical studies
12,13
. 
Currently high-performance liquid chromatographic (HPLC) separation 
systems coupled to mass spectrometry (MS) is the workhorse for detecting and 
characterising drug metabolites. The metabolite data generated by LC-MS analyses 
are in general qualitative in the absence of synthetic reference material, since parent 
drug and the metabolites formed can have dramatically different MS-responses. 
Integrating UV-detectors in these systems can provide at least semi-quantitative data, 
providing that metabolism does not affect the chromophore, and this can be used to 
assess major or minor metabolic pathways. Clearly, quantitative data without 
standards (ideally stable isotope labelled if LC-MS is to be used for quantification), 
particularly from complex in vivo matrices can only be generated using radiolabeled 
compounds and these (like the synthetic standards of the metabolites themselves) are 
rarely available during the discovery phase. Depending upon the spectrometer used, 
with high resolution mass spectrometry (HRMS) the preferred option, a suite of MS-
based experiments can be deployed to help characterize metabolites, e.g. MS/MS, 
MS
n
, MS
e
, mass defect filters (MDFs), neutral losses
14,15
. 
The experienced MS operator can use a variety of strategies including 
knowledge, rules and databases
16
 for metabolite detection and identification (MetID) 
to deduce lists of masses to be monitored. Indeed, all of the major mass spectrometer 
manufacturers offer bespoke metabolite identification software for this purpose. This 
can be supplemented by in silico tools such as IsoScore
17
 or Mass-MetaSite
18,19
 that 
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predict the metabolic fate to guide metabolite detection and identification
20
. The 
expert system Meteor Nexus
21
 includes functionality for linking metabolites predicted 
for phase I and II biotransformations to mass spectrometry data. It highlights matches 
in the graphical depiction of the metabolic tree. Also tools based on the SyGMa
22
 
metabolite prediction method have been successful in supporting MetID efforts for 
drugs
23
, and recently an open source library for LC-MS data processing, 
MassCascade
24
, has been released. Another method is to search for metabolites using 
multivariate statistical analysis of the data (this approach is derived from the 
developing field of metabonomics/metabolomics where normally the data is used to 
deduce the relationships between the metabolism and phenotypic readouts such as 
clinical endpoints
25
). Comparison of the MS data from a sufficient number of samples 
obtained from dosed and control in vitro incubations, or animal experiments, can be 
mined using techniques such as principal components analysis for changes in 
metabolic profiles. Whilst some of these changes may well result from alterations in 
the endogenous metabolites, other changes will be due to the production of drug 
metabolites
26,27
. 
Despite the availability of these MS-technologies, and the various in silico 
aids it is often difficult, or impossible, to assign a full constitutional structure. The use 
of techniques such as (LC-)NMR spectroscopy may enable a more complete structural 
characterization of unknown metabolites provided sufficient material is available
28
. 
However, full metabolite characterization is generally only undertaken on a “for 
cause” basis, or after a compound has entered full development14. In the initial stages 
of discovery programs a simple measure of compound stability (i.e., rate of substrate 
disappearance) in hepatic microsomes or primary hepatocytes may suffice. Based on 
the data generated here, those molecules with greater metabolic stability can then be 
chosen for further investigation and chemical optimization. This type of analysis can 
easily be automated, and medium- to high-throughput metabolic stability assays are 
routinely applied
29-31
. Such assays can also be applied to investigations of a 
compound’s susceptibility to metabolism by specific enzyme systems. 
Once appropriate structures have been selected for lead optimization, 
additional metabolic information helps to identify metabolic “hotspots” so that in vivo 
breakdown can be restricted and exposure improved. Rapid generic analysis based on 
a reversed-phase gradient chromatographic separation may be employed for 
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metabolite profiling. Such methods can indicate the general nature of the 
biotransformations occurring (hydroxylation, dealkylation, reduction, conjugation 
reactions etc.) and provide insights into the SoMs as well as the enzyme classes 
involved. Microsomal systems are also useful for examining candidates for the 
generation of reactive intermediates based on so-called “trapping” experiments32,33. 
Such screening aims to detect both “soft” and “hard” nucleophiles formed as reactive 
metabolites via panels of trapping reagents. 
As programs progress through the discovery phases, studies of more complex 
systems such as hepatocytes will be deployed, giving a more complete picture of 
hepatic metabolism, including further information about the generation of reactive 
intermediates. Finally, keeping in mind potential issues with allometric scaling, 
studies in animals provide the opportunity to investigate the in vivo metabolism, 
distribution and excretion of a selected number of candidate compounds, often using a 
much more bespoke chromatographic separation to maximize the data recovery from 
samples such as urine, bile and tissue extracts. However, the difficulties of obtaining 
truly comprehensive metabolite profiles in the absence of radiolabelled materials (or 
some other tracer) in biofluids should not be underestimated. The presence of 
endogenous metabolites increases the complexity of detection while effects such as 
ion suppression may attenuate signals for candidate drug metabolites. 
COMPUTATIONAL APPROACHES FOR 
INVESTIGATING DRUG METABOLISM 
A wide array of computational methods and integrated approaches have been 
developed for the prediction of drug metabolism, and are distributed in the form of 
web services and as free and commercial software (Table 2)
34,35
. They may be 
classified as specific (“local”) or comprehensive (“global”) tools36,37. Specific models 
apply to certain biomolecules (mainly metabolic enzymes) and/or to specific 
metabolic reactions, while global models are in principle applicable to diverse 
biological systems (i.e. to any metabolic enzyme and biotransformation) and to most 
small organic compounds. The goal of many metabolism software packages generally 
lies in combining various tools and methods not for a single enzyme, but for the 
largest possible number of targets related to drug metabolism. The inclusion of other 
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functional proteins, which may synergize with metabolising enzymes, such as 
transporters (e.g. P-glycoprotein
9
) can also be envisaged. 
Among the most common applications of computational methods is the 
determination of fundamental structural, functional and mechanistic properties of 
biomolecules related to drug metabolism, which enables the identification of 
metabolically labile positions (SoMs) in small organic molecules and the prediction of 
metabolites. Once the chemical structures of the actual metabolites are determined, a 
good starting position for predicting their reactivity, toxicity, bioactivity and other 
pharmacokinetic and pharmacodynamic properties has been obtained. An overview of 
the scope and limitations of computational methods is provided in Table 3. 
 
<<Table 2 approx. here>> 
<<Table 3 approx. here>> 
 
Components to successful prediction of drug metabolism 
Virtually any technique of computational chemistry has been adopted for the 
task of drug metabolism prediction, but it has become clear that the key to success is 
the integration of various methods and resources. 
Component 1: Experimental data 
Computational models are often (but not exclusively) based on experimental 
data, and the amount and quality of the available data will determine their coverage 
and performance. Experimental data are generally generated under controlled 
conditions, meaning that a number of variables are set and kept constant, leaving large 
portions of the space of possibilities unexplored. As an example, the concentration 
and distribution of metabolic enzymes in vivo may not be equivalent to those from 
which the experimental model was derived. Computational models can therefore be 
false, irrelevant, or, at best, incomplete. 
Recently, efforts in making experimental data on small organic molecules 
available to the public have clearly increased
38
, but data on drug metabolism is still 
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sparse. There are only a few databases of relevance to this topic in the public 
domain
35
 (Table 4), and even proprietary data collections are surprisingly limited in 
their coverage. Data collections on metabolism have been built up over decades and 
are often not stored in a machine-readable format. 
Assay technologies, protocols, requirements for new medicines, definition of 
targets and the chemical space of interest etc. have changed during the last years, 
resulting in heterogeneous datasets. Apart from the limited quantity and coverage, 
data quality is a further concern, including issues related to experimental variability 
and errors introduced during data collection, curation and manipulation
37,39,40
. When 
searching the literature (or in-house archives) for metabolic data, one is all too often 
confronted with unconvincingly documented or unsolved constitutional assignments, 
especially for minor metabolites. For example, sites of hydroxylation or conjugation 
(i.e. product regioselectivity) are often left unassigned. Such partly solved metabolic 
structures certainly have some utility, but they must be clearly designated as such to 
avoid an over- or misuse. Configurational (i.e. stereochemical) aspects of metabolite 
formation and characterization have received considerably less attention than 
constitutional aspects
41,42
, despite their obvious pharmacological significance. For all 
these reasons, distilling high quality data that can be used for training computational 
models is a challenging and labour-intensive task that needs to be done by experts. 
Experimental data such as bioactivities can be modelled using (Q)SAR 
techniques. These methods have evolved from univariate statistical approaches to 
multivariate machine learning techniques based on heuristics. Classical (Q)SAR 
methods apply linear regression techniques to fit experimental data. Regression 
(numerical) models have historically been used to model continuous responses (such 
as pKD) from high-quality datasets, while classification (categorical) models are often 
favoured for modelling noisy data (e.g. when collected from different laboratories or 
from assays with a high intrinsic variability). Machine-learning methods generally 
outperform classical approaches on large and highly diverse datasets featuring 
complex non-linear relationships. With the rapid increase of available data these 
methods are becoming increasingly popular, despite obvious drawbacks such as 
limited interpretability
37
. However, it may be unwise to dismiss such models for the 
sole reason of lack of (linear) interpretability. Here, chemists can learn from other 
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disciplines, e.g. physics and engineering, that very successfully employ nonlinear 
modelling approaches for solving complex problems. 
(Q)SAR models have primarily been reported for the interaction of molecules 
with specific CYP isoforms, but also UGTs and sulfotransferases, and receptors 
involved in enzyme induction, in particular the CYP-inducing AhR (aryl hydrocarbon 
receptor), CAR (constitutive androstane receptor), and PXR (pregnane X 
receptor)
37,43,44
. On a broader scale, statistical and machine learning methods are used 
to predict comprehensive bioactivity spectra of small molecules. However, current 
mechanistic models generally do not take into account information beyond target 
annotation, and hence are limited in their ability to predict phenotypes
45
. Linking 
pathway information to targets can hence improve model accuracy. MetaCore and 
MetaDrug46,47, two pharmacology platforms that use comprehensive biological 
networks for estimating the pharmacological effects and risk of small molecules, 
harness this approach. However, the coverage and accuracy of annotated pathways is 
still a work in progress and there is often significantly less overlap between different 
databases of annotated pathways than one would expect. This is often compounded by 
lack of information on tissue expression levels and rate constants for metabolising 
enzymes. There clearly is an opportunity to invest additional effort in this area to 
further increase the reliability of computation models. 
The majority of toxicity models available to date are trained solely on 
toxicological endpoints. These quantitative structure-toxicity relationship (QSTR) in 
general make use of only a few basic chemical descriptors in combination with classic 
linear modelling techniques. They serve primarily as hazard identification tools to 
support the general risk assessment. Only rarely they are derived for exposure-
response relationships that allows the prediction of absolute toxicity in isolation
39
. 
Biotransformation data can be used to derive models for predicting both the 
sites and products of metabolism in an automated fashion. MetaPrint2D
48
, for 
example, generates simple statistical models for SoM prediction from 
biotransformation databases. An extension of this software, MetaPrint2D-React
48
, 
identifies and encodes the type of metabolic reaction observed for specific atom 
environments. The program is able to generate the chemical structures of likely 
metabolites by applying reaction rules to predicted SoMs. Realistically, such data 
mining approaches require thousands of biotransformation records for proper model 
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development, which with the present sparsity of data, is one of their major limitations. 
These methods therefore have a limited applicability. 
 
<<Table 4 approx. here>> 
 
Component 2: Expert knowledge 
Given the limited quality and quantity of available data, and the wealth of 
empirical knowledge that medicinal chemists have accumulated over decades of 
research in drug metabolism, scientists have been keen to devise sets of rules 
(dictionaries) from expert human knowledge, and to develop reasoning engines to 
apply this knowledge to metabolite structure prediction
49
. Knowledge-based 
approaches such as Meteor
21
 predict the sites and products of metabolism by 
scrutinizing a molecule of interest for the presence of target fragments. Their key 
advantage is the provision of the rational basis underlying a prediction (e.g. literature 
references and brief descriptions). However, these tools often generate a 
combinatorial explosion of predictions, as all possible combinations of 
transformations encoded by the dictionary can be performed, for several (usually 
three) generations of metabolites. Without pruning of the product trees produced, 
large numbers of metabolites may be presented to the user, and their analysis requires 
experience and diligence again. Hence the ranking of metabolites and the definition of 
adequate cut-off criteria are key challenges of knowledge-based approaches, which 
requires additional components to be integrated into such expert systems. 
Rule-based systems are also firmly established in predictive toxicology, where 
they are used to interrogate molecules for structural elements linked to toxicity
50
. 
They have received considerable interest from regulatory authorities concerned with 
medicines registration (e.g. 
51
) and are typically included as part of the guidance in 
investigating the toxic liability of new substances including drugs. 
Component 3: Physicochemical properties 
Sufficiently water-soluble compounds are likely to be excreted without 
undergoing metabolism. Expert systems and many other predictors make extensive 
use of this fact and other computed physicochemical properties such as logP 
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(octanol/water) or logD, the pH-dependent partition coefficient, as a means of 
metabolite ranking and filtering. A note of warning is apposite here, since more and 
more physicochemical parameters used in structure-metabolism relationships are 
calculated ones using common software whose limits and levels of precision are 
ignored by users. Also the effects of transporters on excretion of small molecules can 
be profound. For example glucose is almost 100% re-absorbed in the kidneys from 
the ultra filtrate despite being very hydrophilic. 
Component 4: Target structure 
Ligand-based methods need to deal with significant uncertainty about the 
target structure, specifically the ligand-receptor interaction site. Structure-based 
methods additionally take into account structural properties of the target, a key 
component for understanding protein-ligand interactions at an atomic level of detail. 
Only twelve years ago the first crystal structure of a human microsomal CYP (2C9) 
was resolved
52
. Today about one hundred crystal structures of CYPs are available 
covering most isoforms relevant to human drug metabolism. This is a respectable 
collection of potentially valuable data, but it is important to note that these structural 
models cover only a fraction of the enzymes’ conformational space relevant to the 
binding of small molecules
53
. 
Automated ligand docking can be useful for examining whether a specific site 
on a molecule is likely to bind to a specific locus in a target protein. SoMs can be 
predicted by relating the proximity of ligand atoms in a computed docking pose to the 
catalytic centre of the target enzyme. The approach is generally able to correctly 
predict the approximate ligand orientation within the binding pocket (for binding sites 
of low flexibility) and provide a structural hypothesis for the observed biological 
response
53-55
. The technique is particularly valuable for rationalising e.g. diverging 
biological properties of enantiomers. In fact, we advocate the prediction of metabolic 
stereoselectivity be added as a benchmark of the maturity of substrate-enzyme 
docking simulations. Current automated docking methods are not particularly 
promising for 3D-QSAR modelling because of the poor performance of the available 
scoring functions
56
. Specifically, while enthalpic contributions to ligand-receptor 
binding for high affinity molecules are more or less captured by the various scoring 
functions that guide the ligand docking process, the entropic contributions (and other 
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more subtle effects like changes in the heat capacity of the complex) elude these 
techniques. There are remarkable differences in the performance of the various 
docking algorithms but the limitations of this method are primarily defined by 
(structural) data availability (in particular the coverage of relevant protein 
conformations), expert knowledge of the target, the algorithm itself and model 
parameterization. 
Steric and chemical properties of target macromolecules can be described by 
molecular interaction fields (MIFs). MIFs are generated by embedding the target into 
a grid and computing interaction energies with a chemical probe for each grid 
node
57,58
. A probe is a small chemical fragment used to characterize a specific type of 
chemical features, most commonly hydrophobic features and hydrogen bonding 
regions. MIFs can be visualized as isopotential 3D maps indicating the directionality 
and topology of the interactions formed between a ligand and the receptor. MetaSite
59
 
is such an integrated software package for metabolism prediction that is based on 
MIFs. Among several other components, it features a fast docking surrogate method 
to relate the structure of small molecules to CYPs for SoM and metabolite prediction. 
Component 5: Target flexibility 
Metabolic enzymes and effectors involved in their regulation are known for 
remarkable ligand promiscuity. The plasticity and size of their binding sites (some of 
them have two or more) is a direct result of their function, which in the case of 
xenobiotic-metabolising enzymes is to provide a flexible and adaptable system for 
processing a wide range of substrates. Today, molecular dynamics (MD) simulations 
(often in combination with quantum chemical methods) are the most powerful 
theoretical approaches for analysing and predicting the interactions of protein-ligand 
pairs, and much of our knowledge about the structure, function, specificity and 
mechanisms of metabolic enzymes has been derived from these simulations
60,61
. 
MD simulations have revealed conformational changes induced by the binding 
of small molecules
62,63
 to various CYP isoforms and established a relationship 
between substrate specificity and enzyme malleability
64
. They have been employed to 
study the solvation of the active sites of various CYP isoforms
65
, and the active site 
access and egress pathways, which might play a key role in substrate selectivity and 
specificity
66,67
. Various methods have been developed to enhance conformational 
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sampling, including the application of an artificial force applied to the ligand in order 
to pull toward a specific (steered MD simulation
68
) or random (random accelerated 
MD simulation
69
) direction. The fact that the dynamic motions of CYPs are affected 
by their binding to membranes introduces another layer of complexity to their 
analysis
60
. 
Free energy (pathway) methods such as free energy perturbation
70
, 
thermodynamic integration
71
 and the Bennett acceptance ratio method
72
 allow the 
calculation of the free energy of binding with a mean absolute error typically ~1.5 
kcal/mol
73
 (NB: the difference between a high and a low affinity analogue is only a 
few kcal/mol). These methods also come at high computational cost
24
. Faster free 
energy methods (such as LIE
74
) have been developed, but they are generally less 
accurate
73
. Free energy methods have been employed e.g. to study the binding of the 
acidic and lactone forms of atorvastatin to CYP3A4
75
, the stereoselective metabolism 
of CYP substrates, and the impact of mutations on substrate affinities
76,77
. 
MD simulation methods come with considerable demands in computational 
power and human expertise. Therefore they have mostly been applied a posteriori for 
studying the time-dependent structural and electronic properties of the most important 
metabolic enzymes. GPU technology with faster MD algorithms is boosting 
capabilities to sample the phase space more comprehensively
78
, but the setup of the 
simulation (protein preparation, ligand parameterization) in particular, and the 
respective analysis remain laborious and accessible to experts only. Data can be 
complex, “Big”, and overwhelming, therefore there is a need to develop more 
efficient ways to decode the crucial bits of information. Various clustering techniques 
can be used to elucidate representative protein conformations that could be used for 
automated docking
79
. The many options to consider: water molecules, solvation, 
protonation and other factors, result in a very large number of possible receptor 
models. From a computational point of view this is generally not a limitation as 
molecules can be easily docked against thousands of protein structures within a short 
period of time. The problem lies again with the insufficient performance of scoring 
functions, leaving the question of which docking pose to trust. 
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Component 6: Reactivity 
Reactivity is the major determinant of drug metabolism (at least for CYP-
mediated biotransformations
80
), and quantum mechanical (QM) methods allow its 
study at an electronic level of detail. Regarding metabolism as a hypothetical two-step 
process, the molecule must fit into the active site, and then must be sufficiently 
activated by the enzyme to undergo metabolism. QM systems generally take into 
account only the most proximate protein environment that is directly involved in a 
chemical reaction but ignore effects originating from the more distant protein 
environment. But even with these abstract representations of enzyme systems, fairly 
accurate predictions for specific metabolic reactions are possible
81
. 
With MD simulations and QM methods having complementary properties, it 
comes as no surprise that the combination of both approaches, referred to as quantum 
mechanical/molecular mechanical (QM/MM) methods
82
, has become a key 
technology for investigating enzyme reactions
61,83
. The idea of the QM/MM hybrid 
approach is to tackle large systems by describing the region where a chemical reaction 
takes place by a QM method while accounting for effects of the environment by MM 
methods. QM/MM methods have been extensively used for investigating the catalytic 
cycle of metabolic enzymes, primarily that of CYPs
61,83
, but also of epoxide 
hydrolase
84
 and glutathione S-transferases
85,86
, for example. Reaction intermediates 
can be unstable with very short lifetimes, which makes them extremely challenging to 
observe with experimental approaches. Knowing their chemical structure is of 
immediate relevance to drug discovery, as it allows the rational design of molecules 
with specific binding properties (in particular substrates or inhibitors). This is an area 
of research where QM/MM methods can be effective. 
A new direction to the QM calculation of full proteins is being explored 
utilising fragmentation methods like divide-and-conquer or fragment molecular 
orbital theory (FMO)
87
, where the protein is split into terminally capped amino acid 
fragments to be calculated locally and an overall energy extracted from their pair 
interaction energies. Specifically designed GPU (graphics processing unit) based 
algorithms like TeraChem
88
 allow for even QM molecular dynamics simulations of 
full proteins in an MM solvent environment. 
Calculating molecular flexibility and/or reactivity is a non-trivial task, and it is 
important to note that such models depict one specific protein-ligand interactions or 
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enzyme mechanism only. They are also computationally fairly expensive, which is a 
further complication in the implementation of such methods in drug discovery 
workflows. Fast QSAR methods have therefore been preferred in an attempt to 
incorporate reactivity implicitly through chemical descriptors
89,90
. Also these are 
generally confined to a specific type of metabolic reaction. Machine learning methods, 
on the other hand, are able to encode a whole range of different metabolic reactions, 
which is one of the main reasons for the popularity of these methods, including 
support vector machines (SVMs), artificial neural networks (ANNs) and random 
forests. The types of chemical descriptors used for encoding SoMs, their numbers and 
level of sophistication are in fact remarkable. The spectrum ranges from FAME
91
, a 
random forest model for phase I and II metabolism that uses only seven molecular 
descriptors, to RS-Predictor
92
, an SVM model for CYP-mediated metabolism which 
employs more than 500 chemical descriptors. 
Component 7: Metabolic networks - systems biology 
Comprehensive models (simulators) of drug metabolism require the ability to 
correctly predict a whole cascade of events and properties of the system to allow the 
estimation of biological effects. This would involve accurate knowledge and 
prediction of the (i) concentrations and distribution of the drug, (ii) metabolic 
liabilities (SoMs), (iii) chemical structure of metabolites, (iv) interactions with 
pharmacologically and toxicologically relevant biomolecules, (v) reaction rates and 
(vi) tissue concentration and localisation of enzymes and cofactors. While prediction 
of likely metabolites is feasible, it is challenging to ascertain their pharmacological 
and toxicological relevance in the context of the biological system. Target prediction 
tools allow the identification of likely ligand-protein interactions and possibly 
extrapolation to the contribution of these interactions to prediction of phenotypic 
effects using QSAR techniques. However, pharmacological effects are strongly linked 
with reaction rates and metabolite concentrations in specific tissues, which themselves 
are to a significant extent influenced by many factors including the activity of 
transporters. Possibly, these will only be reliably estimated if binding, ligand 
recognition and unbinding processes (pharmacodynamics) are understood at an 
atomic level of detail. Metabolic rates are specific to an enzyme and a substrate. 
Regardless of the structural or chemical significance of changes to substrates, these 
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can have a huge impact on the binding and unbinding processes (which SoM and 
metabolite prediction algorithms typically do not include), and consequently, on 
metabolic rates
93
. Chemical modifications of one part of a molecule to increase its 
metabolic stability may in fact lead to metabolic switching, resulting in the expedited 
biotransformation at another position in the molecule. As a consequence, prediction of 
metabolic rates, if possible at all, is only feasible within an extremely narrow and 
well-defined chemical space
93
. Even if metabolic rates could be obtained, it is still a 
far cry from being able to estimate effects of metabolites on a biological system, in 
particular as metabolic processes and biological responses can be highly specific to 
the individual
13
. 
Integrated computational approaches 
Integrated computational approaches combine a variety of data sources, 
models, and algorithms in order to boost applicability, information content, and 
significance and prediction success rates, with the ultimate goal of rendering a (more) 
complete picture of physiological processes. One common strategy is to combine 
ligand- and structure-based methods. It has been shown that both have their individual 
methodological advantages and disadvantages, and there is no clear preference for a 
single method
43,94
 but a lot to gain by their combination. The targeted use of 
consensus approaches and composite modelling workflows represent further 
established strategies for improving the accuracy and significance of predictions, e.g. 
for the task of bioactivity profiling
95,96
. Pathway information and network analysis 
algorithms have been successfully integrated for predicting the pharmacokinetic and 
pharmacodynamic properties of drug molecules
46,47
. Integration of data 
types/resources and algorithms has also become a major driver of tools for 
regioselectivity and metabolite prediction. For example, knowledge-based systems 
use physiochemical property estimators and QC methods to flag potentially toxic 
metabolites and reduce false-positives rates. The latter has also been addressed by 
implementing docking as a post-filtering tool for generated metabolites
97
. MetaSite 
uses MIFs derived from the protein structure structural data, combined with a 
fingerprint-based algorithm (fast docking surrogate method) and a QC approach 
(reactivity estimator). The importance for including reactivity, steric accessibility and 
pharmacophoric constraints has been studied in detail for SMARTCyp
80,98,99
, but in 
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fact most statistical and machine-learning approaches make use of descriptors that 
encode these components. 
BEST OF BOTH WORLDS: INTEGRATION OF 
EXPERIMENT AND COMPUTATION 
A broad portfolio of experimental and theoretical methods for studying 
metabolism at different levels of sophistication is available today. It is important to 
realise that when used independently, any of these approaches illuminate only specific 
aspects of drug metabolism and ignores most of the others. In contrast, the 
combination of various experimental and theoretical approaches will generate a fairly 
complete picture of a compound’s metabolic fate. One would assume that synergies 
created by the integration of both domains has long been harnessed by the 
pharmaceutical industry, when in fact it seems that there is still some way to go to 
reach this point. The reasons for this situation are manifold: limited resources, costs of 
process restructuring, organizational structures, timelines for learning cycles, 
diverging (and in part incompatible) schools of thought, and the limitations of current 
methods. A key problem is the open availability of relevant and diverse data, which is 
often secured in pharmaceutical companies and CROs. Sharing these data is often 
impossible due to intellectual property constraints. However, solving this problem 
will provide data related to a broader chemical space and thereby increase the 
applicability domain of computational prediction models. 
Departments for computational and experimental research of drug metabolism 
are traditionally operated as well-separated “silos”. Scientists of both areas have 
different backgrounds, use distinct terminologies, and are focused on applying their 
acquired expertise. Depending on the organizational setup of research organisations or 
projects, the level of integration of drug metabolism research varies greatly. 
Computational tools may be used by experts in drug metabolism and/or by 
computational or medicinal chemists. The latter tend to focus on SAR and synthesis. 
Computational chemists may not have expert knowledge in pharmacokinetics, and 
sophisticated theoretical methods may not necessarily be within the comfort zone of 
specialists in drug metabolism. Close interplay of the different disciplines is therefore 
of utmost importance to tackle the problem of metabolism prediction. Efficient 
communication allows the development of appropriate models based on in-house data 
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to guide metabolic optimization. Early access to data on microsomal or hepatocyte 
stability is required. A recent example for the successful liaison of experimental and 
theoretical approaches is the optimisation of the metabolic stability of 
mineralocorticoid receptor antagonists reported in Box 2. But there is room for 
improvement, in particular with respect to modelling CYP induction, the rate and 
extent of metabolic reactions, and the prediction of phase II metabolism. 
 
<< Box 2 approx. here>> 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
A plethora of powerful in vitro assay and analytical technologies are at our 
disposal, allowing us in principle to obtain a fairly complete and accurate picture of 
metabolic processes. Whilst it is likely that robust and cost-effective metabolite 
generating systems such as hepatic microsomes will continue to provide a solid 
bedrock for metabolite generation the development of so-called 3D bioreactor (“organ 
on a chip”) technology is a rapidly developing field. These systems provide a much 
more “organ-like environment” for cells, which can be maintained for long periods 
whilst being exposed to drugs in order to assess metabolism and toxicity
100-102
. If, as 
seems likely, such bioreactors (which are not limited to hepatocytes) can be made into 
a robust and easily deployed technology this will represent a major advance for in 
vitro techniques. 
Analytical techniques for drug metabolite detection and identification are 
likely to remain focussed on the use of MS-based technologies of ever increasing 
levels of sophistication and sensitivity for the foreseeable future. The development of 
robust miniaturized separation systems will further drive down the sample 
requirements
103
. Another promising development is the application of ion mobility 
spectrometry (IMS), which can enhance metabolite separation and, by additional 
characterization capability, improve SoMs identification. The approach is based on 
separating isomeric species depending on differences in their IMS drift times, which 
are linearly proportional to the collision cross-section reflecting physical size and 
shape
104,105
. Fundamental progress in SoM and metabolite prediction would result 
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from improvements in the reporting of additional metadata on the origin (tissues, 
genomes, experimental conditions etc.) of samples, complete identification of major 
and minor products, improved experimental and statistical software tools for the 
normalisation of mass spectral data, integration with transport phenomena and 
experimental data on the concentrations and rates of reaction. 
Rapid advances can also be expected in the development of new animal 
models, either based on the engraftment of human cells into animals such as those 
seen in the “chimeric humanized” mice or animals genetically modified to contain 
human drug-metabolising enzymes and transporters. These models can be expected to 
provide much more accurate predictions of the metabolic and pharmacokinetic 
properties of candidate drugs in humans
10,11
, but certainly raise ethical issues. 
Experimental approaches to investigate metabolism come with substantial 
demands in technical resources and human expertise. This is where computational 
chemistry can introduce a big leap forward in metabolism research. Computational 
prediction of drug metabolism is still a young field of research but in silico methods 
do not only have the potential to guide or (partially) replace experimental efforts, they 
may also be the method of choice to investigate catalytic processes and highly 
reactive species. The most obvious synergy to gain from the combination of both 
domains is from coupling of software and spectroscopic instruments for more 
efficient metabolite identification and characterization. Manufacturers of mass 
spectrometers are vigorously pursuing this. 
Today drug metabolism is typically addressed in the industrial setting rather 
than academia, with the consequence that software and data are generally withheld 
and not available to the scientific community at large. However, the tide seems to be 
turning and the field of cheminformatics appears to be finally making much more 
program code and data available to the scientific community. Data on the sites and 
products of metabolism, metabolite concentrations and tissue locations of 
metabolising enzymes are being harvested and incorporated into various databases 
which address different aspects of metabolism, including drug and agrochemical 
metabolism in a variety of species of plants and animals. The information stored 
ranges from data that is semantically rich to numerical data on concentrations and 
locations of metabolites. Annotated metabolic pathways and data on transporters 
complement this picture. 
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Metabolism is an example of an emergent process, and the complexity of the 
system is influenced by many extraneous and individual factors. Current 
computational approaches take little account of these and other factors including 
transporters, proper consideration of metabolising enzymes other than CYPs, 
environmental factors, and in particular the concentrations, metabolic networks and 
rates of metabolism of metabolising enzymes. Substantial progress is being made in 
gathering data for pharmacokinetic/pharmacodynamic (PK/PD) modelling, and this 
will have a significant effect on prediction not just which metabolites are present, but 
also their concentrations and flux over time. In addition, the emerging field of 
metabonomics attempts to connect the metabolic state of an individual or population 
to phenotypic measures. This covers the whole gamut of metabolic research, 
instrument design and measurement protocols to machine learning and clinical 
prediction. There is enormous potential in this area to combine all the experimental 
and theoretical methods to improve patient stratification and clinical outcomes. 
We will continue to see substantial gains in computational power, driven by 
GPU and cloud technology, increasingly efficient algorithms, and advances in parallel 
computing. This will open up many new avenues for the development and application 
of highly accurate methods for the simulation of biomolecules and indeed whole 
biosystems. 
For experimental and theoretical approaches alike, human expertise remains 
an important ingredient. The broad range of disciplines involved at the cutting edge of 
predictive drug metabolism is impressive. It draws on chemistry (physical, organic-
synthetic, analytical, medicinal etc.), biology (biochemistry, enzymology, genetic, 
epigenetics etc.), pharmacology (molecular, clinical, pharmacokinetic, toxicology, 
therapeutics etc.), and computational components (software development, quantum 
chemistry, simulations, statistics, machine learning etc.). For all of these experimental 
and theoretical domains of research, there is no technology available to date that is 
superior in all relevant scenarios. Bringing experimentalists and theoretical scientists 
closer together will result in progress. Ideally, a feedback loop of experiment, design 
and testing would greatly improve predictive models, as much of the present work has 
concentrated on retrospective analysis. In the future, closer collaboration is needed to 
further develop these models. The central role that metabolism plays in biology and 
the requirement that predictive models be incorporated into a wide variety of research 
 22 
and development programs (e.g. drug discovery, environmental science, clinical 
phenotyping, pesticide development) means that significant resources will be applied 
and progress in understanding and in generating predictive models will continue. 
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ELEMENTS 
Box 1. The many implications of drug metabolism 
Categories of drugs with respect to their metabolic behaviour 
Soft drugs have (or, are designed for) fast and predictable metabolic 
transformation into inactive, nontoxic metabolites (often via conjugation or hydrolysis 
reactions)
106
. Examples include succinylcholine and esmolol. Metabolically stable (or 
highly resistant) drugs, on the other hand, are excreted without undergoing 
metabolism. Examples include lisinopril and bisphosphonates. 
Drugs with active or highly active metabolite(s) include cisplatin ( 
monoaqua and diaqua species), diazepam ( nordiazepam), encainide ( O-
desmethylencainide and 3-methoxy-O-desmethyl encainide), morphine ( morphine-
6-O-glucuronide), tamoxifen ( 4-hydroxytamoxifen and endoxifen), and tramadol 
( O-desmethyltramadol) 
Metabolites with comparable or improved therapeutic properties 
marketed as drugs include oxazepam ( diazepam), cetirizine ( hydroxyzine), 
desloratadine ( loratadine), paracetamol ( phenacetin), and fexofenadine ( 
terfenadine). 
Prodrugs are medicinal compounds whose complete, or nearly complete 
therapeutic potential is based on the activity of the metabolite(s)
107-111
. Chemical 
groups liable to metabolism are often introduced to improve ADME (absorption, 
distribution, metabolism and excretion) properties or to reduce toxicity (e.g. 
chemotherapeutics). Examples include enalapril ( enalaprilat), fenofibrate ( 
fenofibric acid), levodopa ( dopamine), oseltamivir ( oseltamivir carboxylate), 
and valaciclovir ( aciclovir). 
Changes in pharmacological activity 
Drug metabolites can range from intrinsically inactive to highly active, on the 
identical pharmacological target as the parent drug or any other biomolecule
4,112-114
. 
Gain in pharmacological activity: 
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Metabolism can produce active species that contribute to the therapeutic 
activity of drugs, and this actually is not a rare event. In the past drugs were often 
developed and almost solely guided by animal models, and it could happen that the 
observed biological response was to a significant part (or even completely) a result of 
an active metabolite and not the parent
113
. 
Gain of therapeutic activity may be observed for metabolites with favourable 
physicochemical properties for disposition, assisting transfer to their pharmacological 
target. Also chiral inversion as a result of metabolism may lead to severe changes in 
biological activity/toxicity. Metabolites may be (preferred) substrates of influx 
transporters. 
Loss of pharmacological activity: 
Extensive biotransformation of metabolically unstable molecules into inactive 
or rapidly excreted metabolites can result in a substantial drop or complete loss of 
therapeutic efficacy. This is in principle predictable and assays are available that can 
identify problematic molecules. Metabolic instability is particularly challenging if 
drug metabolism is induced as part of a resistance mechanism (most commonly 
observed for anti-infectives and anti-cancer drugs). Metabolites may also be 
substrates of efflux transporters. 
Toxicity 
Biotransformation bears the risk of unwanted toxification, resulting in adverse 
drug reactions (ADRs)
4
. 
On-target ADRs (in the context of metabolism) are a result of exceedingly 
high concentrations of a drug or an active metabolite, sometimes in a non-target tissue. 
They are generally dose-dependent and in principle predictable. 
Off-target ADRs result from the interaction of a drug or its metabolite(s) with 
a non-intended target. A relevant example is cardiotoxicity caused by several (often 
but not exclusively) lipophilic drugs belonging to various pharmacological classes by 
blocking the human ERG potassium channel at therapeutic doses
115
. Off-target ADRs 
are generally dose-dependent and in principle predictable. 
ADRs involving reactive metabolites are a reason for concern because they 
can involve covalent binding to biomolecules (adduct formation) and/or oxidative 
 34 
stress following the formation of reactive oxygen species
116,117
. They are in principle 
predictable (or rationalisable) and dose-dependent. 
Idiosyncratic drug reactions are rare (< 1 case in 5000) but with potentially 
severe consequences (anaphylaxis, blood dyscrasias, hepatotoxicity, and skin 
reactions). They are not currently predictable and apparently dose-independent. Their 
underlying mechanisms are poorly understood but are often thought to be associated 
with reactive metabolites
118
. 
Drug-drug interactions 
Drug-drug interaction refers to the situation where the drug concentration 
present at (anti-) target sites is changed dramatically by the interference of another 
substance with drug-metabolising enzymes or related biomolecules. Potential 
outcomes of drug-drug interactions are (i) loss of pharmacological efficacy due to 
enhanced clearance, (ii) toxic effects caused by accumulation, and (iii) increase of the 
rate of reactive, toxic intermediates formed. They can be life threatening. For example, 
monoamine oxidase inhibitors are well known for potentially lethal dietary
119
 and 
drug
120,121
 interactions, and hence they are currently used only as a last resort for the 
treatment of atypical depression. 
Drug resistance 
Induction of metabolic pathways is a major route of drug resistance, in 
particular for anti-infectives and cancer drugs, but this also has huge implications for 
the effectiveness of pesticides. Multidrug resistance can also be driven by active 
efflux facilitated by transporters
122
. 
Changes in physicochemical properties 
Biotransformation has an impact on physicochemical properties
6
 and hence 
pharmacokinetics, in particular with respect to distribution and excretion. It also 
affects parameters such as absorption, passive membrane permeation, transport, 
binding to macromolecules etc.
9,12
. 
 
<< END OF BOX 1>> 
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Box 2. Combination of experimental and theoretical 
approaches to analyse and predict drug metabolism: An 
example from real life 
The fruitful combination of experimental and computational approaches to 
optimize metabolic compound stability in a pharmaceutical industry setting can be 
exemplified by the work on a series of potent and selective non-steroidal 
mineralocorticoid receptor antagonists from a lead optimization project at Bayer 
Healthcare
123
. Since metabolite identification (MetID) assays are limited in 
throughput, most of the optimization of metabolic properties was done via in vitro and 
in vivo stability assays combined with sites of metabolism (SoM) prediction with the 
Bayer in-house software CypScore
89
. Additionally, in silico prediction allowed 
profiling of alternative designs before synthesis. In the course of the project, hundreds 
of compounds and metabolites were predicted in silico, whereas only a small amount 
of MetID experiments could be performed. 
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Mineralocorticoid receptor antagonist 1 showed low metabolic stability in 
hepatocytes with an Fmax (percentage of compound remaining) of 21% and also high 
blood clearance (CL) in rat of 4.2 L/(h×kg). Via MetID assay experiments in human 
and rat liver microsomes, oxidation of the of the 5- (or 6-) position of the indole and 
two-step oxidation of the methyl group leading first to the alcohol and then the acid 
were identified as the main metabolites. CypScore SoM predictions for 1 and the (not 
synthesized) metabolite 1-MET were in accordance with experiment, but for 1-MET 
an additional weaker SoM was predicted at the carbon in the α-position to the cyano 
group. There was no experimental in-house evidence for such a metabolic reaction. 
In accordance with target SAR, the methyl group was replaced with a nitrile in 
2, which as expected resulted in an increase of stability for rat hepatocyte, Fmax to 
34%, but not as much as expected. The major SoM was now the aromatic edge, but 
again accompanied by the weaker predicted SoM at the α-carbon of 2, which was now 
also identified via MetID. Based on target fit and SoM prediction, the chain length 
was successfully reduced by one carbon leading to 3. This increased the Fmax value 
to 63%. Further metabolic stabilization was consistently achieved by introducing 
derivatives with fluorination in the 5-position. 
The metabolically labile methyl group in compound 1 was also replaced by 
various other substituents of different size, hydrophobicity and polarity. Several 
active sulphonamides were prepared that turned out to reduce the liability of the 
aromatic fragment, as exemplified by the low-clearance compound 4 with an Fmax = 
75% and rat plasma clearance of 1.4 L/(h×kg). 
This example shows the successful combination of various in vitro and in vivo 
experiments with in silico models to optimize the metabolic stability and in parallel 
target activity of a compound series. 
 
<< END OF BOX 2>> 
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Figure 1 
 
Figure 1. Shapes of cytochrome P450 binding pockets differ according to the 
class. The cluster diagram in the centre of the figure represents a grouping of the 
enzymes based on the shape and “buriedness” of their heme-containing active 
sites. Cartoons of substrate-free pockets are shown for selected cytochrome 
classes. The pockets were automatically extracted using the software 
PocketPicker
124
. Note that CYP2 and CYP3 families have evolved as essentially 
xenobiotic metabolising enzymes, whereas CYP11 and CYP46 are two among the 
many CYP families playing essential physiological roles. Colour intensity 
indicates the local buriedness (dark colour: Far from the protein surface, light 
colour: Surface exposed). 
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Table 1. Experimental Methods for Characterising 
Metabolic Stability and Identifying Sites of Metabolism. 
 
Experimental approach Scope 
Incubations with individual drug-metabolising 
enzymes e.g. CYPs, UGTs  
Method for determining enzyme involvement and 
specificity, mechanism–based inhibition and drug-
drug interactions. 
Microsomal incubations + NADPH More detailed determination of oxidative 
metabolism, metabolic stability. 
Microsomal incubations + UDPGA Determination of glucuronidation. 
Incubations with hepatocytes (from a range of 
species including human) 
Determination of hepatic metabolite profiles 
including conjugations and reactive metabolite 
trapping, and metabolic stability. 
Specific reactive metabolite trapping in 
microsomal incubations, trapping of soft 
nucleophiles using e.g. glutathione or cysteine, 
and hard nucleophiles with e.g. cyanide. 
Identification of hot spots leading to reactive 
intermediates, using high resolution MS or, in 
complicated cases, NMR for precise structures. If 
reactive intermediates are detected, LC-MS-based 
proteomics can be used for further identification 
of sites of binding and nature of the reactive 
intermediate. 
If radiolabelled compounds are available then 
quantitative studies of covalent binding of reactive 
intermediates to proteins can be performed. 
Animal models: Most commonly rodents (mouse 
and rat), including complex models designed to 
look at e.g. biliary elimination. Newer models 
include genetically modified and “humanized” 
strains (usually mice) as well as “chimeric” 
animals containing e.g. human hepatocytes. 
Used to solve problems where e.g. in vivo 
pharmacokinetics are poorly predicted by in vitro 
studies, e.g. due to unchanged excretion, drug-
drug interactions or more information on 
compound distribution is needed.  
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Table 2. Computer Software Used in Drug Metabolism Prediction.
a,b
 
Predicting regioselectivity Core 
component(s) 
Type Coverage Licensing Description 
MEXAlert
125
 rules LB, 2D phase II commercial Quick screening tool to identify metabolically unstable 
molecules. 
QikProp
126
 rules LB, 2D ~20 phase I reactions commercial Fast SMARTS pattern matcher for predicting SoMs for 
phase I reactions. 
MetaSite
59
 molecular 
interaction fields 
+ reactivity 
estimator 
SB, 3D variety of CYPs commercial Uses MIFs derived from protein structures plus molecular 
orbital calculations to identify likely SoMs. 
P450 Site of Metabolism 
Predictor
127
 
induced-fit 
docking + 
reactivity 
estimator 
SB, 3D CYPs 2C9, 2D6, 3A4 commercial Induced fit docking approach in combination with a 
quantum chemical model. 
SMARTCyp
128,129
 DFT-derived 
reaction energies 
LB, 2D CYPs 1A2, 2A6, 
2B6, 2C8, 2C19, 
2E1, 3A4 
free, open source Utilizes a set of pre-computed activation energies in 
combination with topological accessibility descriptors. 
Available also as free online service. 
StarDrop P450 Metabolism 
Prediction module
130
 
semi-empirical 
method 
LB, 3D CYPs 2C9, 2D6, 3A4 commercial Combines quantum chemical analysis with a ligand-based 
model of CYP substrates to identify SoMs. Takes into 
account calculated logP values. 
CypScore
89
 surface 
electrostatics + 
semi-empirical 
method 
LB, 3D Individual CYP 
reactions 
free 
reimplementation 
available; requires 
commercial 
software 
components  
Collection of six MLR models to cover the major reaction 
types of CYPs. 
Metaprint2D
48
 atom mapping; 
statistical model 
LB, 2D phase I+II free, open source Derives likelihoods of metabolic transformation for atoms 
with a defined atom environment by mining large 
biotransformation databases. Available also as free online 
service. 
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ADMET Predictor 
Metabolism module
131
 
ANN ensemble LB, 2D CYPs 1A2, 2A6, 
2B6, 2C8, 2C19, 
2C9, 2D6, 2E1, 3A4 
commercial Derives likelihoods of metabolic reactions using ANN 
ensembles on a large, curated dataset. 
Percepta P450 
Regioselectivity module
132
 
PLS (GALAS) LB, 2D human liver 
microsomal 
metabolism and 
CYPs 1A2, 2C9, 
2C19, 2D6, 3A4 
commercial Global partial least squares-based QSAR model for 
calculating baseline regioselectivity; local corrections 
according to training data. Predicts and ranks major 
reaction types. 
RS-WebPredictor
133
 MIRank (SVM) LB, 2D CYPs 1A2, 2A6, 
2B6, 2C8, 2C9, 
2C19, 2D6, 2E1, 3A4 
free Array of pre-trained SVM models using topological 
descriptors and SMARTCyp reactivities for predicting 
SoMs. Intuitive web service. 
FAME
91
 random forest LB, 2D phase I+II free for academic 
use 
Set of random forest models for predicting phase I and II 
metabolism in different species. Trained on drugs, drug-
like molecules, endogenous metabolites and natural 
products. 
Predicting metabolites Core 
component(s) 
Type Coverage Licensing Description 
MetabolExpert
134
 knowledge-
based system 
LB, 2D phase I+II commercial Knowledge base containing rules and lists of substructures 
that inhibit or promote the reaction. Uses logP for filtering 
metabolites likely to be directly excreted. Predicts 
pathways in animals, plants or through photodegradation. 
Meta-PC
135
 knowledge-
based system 
LB, 3D phase I+II commercial Uses a large biotransformations dictionary. Analyses 
metabolite stability using quantum mechanical 
calculations and predicts pathways in mammals, through 
aerobic and anaerobic biodegradation. 
Meteor Nexus
21
 knowledge-
based system 
LB, 2D phase I+II commercial Employs a collection of knowledge-based 
biotransformation rules defined using a dedicated structure 
representation language. User-accessible knowledge base 
to aid the decision-making process. Considers calculated 
logP values for predictions. Latest version includes 
SMARTCyp. 
MetaDrug
136
 knowledge-
based system 
LB, 2D phase I+II commercial Derived from a large knowledge base (MetaBase). 
Generates metabolites from a dictionary of 160 rules. 
Predicted metabolites are rank-ordered and can be directly 
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assessed regarding their pharmacological potential and 
toxicity. 
TIMES
137
 knowledge-
based system 
LB, 2D phase I+II commercial Employs a biotransformation library and a heuristic 
algorithm to generate metabolic maps. Dedicated models 
for skin metabolism, rat in vitro (S9) and in vivo 
metabolism. 
SyGMa
22
 knowledge-
based system 
LB, 2D phase I+II available to 
academia 
Predicts structures of likely metabolites based on rules 
derived from statistical analysis of several thousand 
biotransformations. Assigns probability scores to each 
metabolite. 
EAWAG-BBD Pathway 
Prediction System
138
 
knowledge-
based system 
LB, 2D phase I+II free Rule-based system specialized in microbial catabolic 
metabolism of environmental pollutants. Classification of 
metabolites with respect to their likelihood. Intuitive web 
service. 
JChem Metabolizer
139
 knowledge-
based system 
LB, 2D phase I (can be 
extended to phase II) 
commercial Enumerates all possible metabolites of a given compound. 
Prognosis on metabolic pathways, major metabolites and 
metabolic stability. Species-specific predictions of 
metabolites. 
Metaprint2D-React web 
server
48
 
atom mapping; 
statistical model 
LB, 2D phase I+II free Generates structures of likely metabolites based on the 
MetaPrint2D data mining approach (using SMIRKS 
patterns). Intuitive web service. 
MetaSite
59
 molecular 
interaction fields 
SB, 3D CYP commercial Produces a comprehensive set of metabolites from a 
collection of metabolic reactions. Calculates exact mass 
and relative retention times. Generated metabolites can be 
used for automated metabolite identification in Mass-
MetaSite. 
Predicting interactions of 
drugs with metabolising 
enzymes 
Core 
component(s) 
Type Coverage Licensing Description 
Percepta P450 Specificity 
module
132
 
PLS (GALAS) LB, 2D CYPs 1A2, 2D6, 
2C9, 2C19, 3A4 
commercial Collection of CYP models for predicting inhibitors and 
substrates. Based on same training data and modelling 
technique as the Percepta regioselectivity predictor (see 
above). Reports reliability measure for individual 
predictions. 
Percepta Microsomal random forest LB, 2D human liver 
microsomal 
commercial Random forest model for classifying small molecules into 
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Stability module
132
 metabolism metabolically “stable”, “unstable” or “undefined”. 
isoCyp
140
 SVM LB, 3D CYPs 2C9, 2D6, 3A4 commercial Classification model based on 2D descriptors. Works 
under the assumption that any input molecule is substrate 
of one of the three isoforms. 
MetaDrug substrate 
models
136
 
recursive 
partitioning 
LB, 2D CYPs 1A2, 2B6, 
2D6, 3A4 
commercial Collection of models for identifying substrates and 
inhibitors of important CYPs. Use recursive partitioning in 
combination with atom-centred fragment descriptors. 
Fully integrated into the MetaDrug pharmacology 
platform (web interface). 
MetaDrug inhibitor 
models
136
 
recursive 
partitioning 
LB, 2D CYPs 1A2, 2C19, 
2C9, 2D6, 3A4 
commercial 
MetaPred web server
141
 SVM LB, 3D CYPs 1A2, 2C9, 
2C19, 2D6, 3A4 
free SVM model for predicting CYPs metabolising drug-like 
molecules. 
ADMET Predictor 
Metabolism module
131
 for 
substrates 
ANN ensemble LB, 2D CYPs 1A2, 2A6, 
2B6, 2C8, 2C9, 
2C19, 2D6, 2E1, 3A4 
commercial Predictor based on large curated dataset. Covers the most 
important CYPs and includes a dedicated model for 
predicting inhibitors of human liver microsomes. 
Predicts Km and Vmax values for hydroxylation reactions 
and CLint resulting from the action of five CYPs. 
ADMET Predictor 
Metabolism module
131
 for 
inhibitors 
ANN ensemble LB, 2D human liver 
microsomes and 
CYPs 1A2, 2C19, 
2C9, 2D6 and 3A4 
commercial 
WhichCyp
142
 web server SVM LB, 2D CYPs 1A2, 2C9, 
2C19, 2D6, 3A4 
free Web service for predicting the selectivity of CYP 
inhibitors using SVM models derived from high-
throughput screening data. Uses molecular signatures
143
 as 
descriptors. 
VirtualToxLab
144
 docking + QSAR LB + SB, 
3D 
CYPs 1A2, 2A13, 
2C9, 2D6, 3A4 
commercial; free 
version available 
Uses flexible docking in combination with a multi-
dimensional QSAR approach to predict ligand interaction 
with 16 proteins, including CYP1A2, 2A13, 2C9, 2D6 and 
3A4. 
ADMEWORKS 
Predictor
145
 
MLR LB, 2D 
and 3D 
CYP3A4 inhibitors 
CYP2D and 3A4 
substrates 
commercial Collection of MLR-based QSAR models for the prediction 
of Ki values for CYP3A4 inhibition and Km values for 
CYP2D and 3A4. Classification model for CYP3A4 
inhibitors. 
Predicting toxicological 
effects of metabolites 
Core 
component(s) 2.1.1.1.1.1.1.1.1 T
y
p
e 
Coverage Licensing Description 
 43 
DEREK Nexus
21
 knowledge-
based system 
LB, 2D broad range of 
toxicological 
endpoints 
commercial Predicts toxicological profiles by evaluating evidence for 
and against a broad collection of endpoints. Literature 
lookup functionality for examination of data underlying a 
prediction. 
HazardExpert
146
 knowledge-
based system 
LB, 2D 7 different toxicity 
classes 
commercial Identifies toxic molecules based on fragments. Also 
calculates bioavailability, accumulation, and other 
parameters. 
VirtualToxLab
144
 docking + QSAR LB + SB, 
3D 
16 target proteins commercial; free 
version available 
Docking and QSAR hybrid approach for predicting 
activity on hERG, hormonal receptors, drug metabolising 
enzymes and their modulators. 
MetaDrug
136
 recursive 
partitioning 
LB, 2D 70 models for 
compound toxicity, 
ADME and 
therapeutic activity 
commercial Systems pharmacology platform built on data from 
MetaBase. Prediction of mechanism of action, toxicity, 
and off-target effects. 
Leadscope toxicity 
models
147
 
partial logistic 
regression 
LB, 2D 8 sets of models for a 
broad range of 
toxicological 
endpoints 
commercial Collection of models for adverse cardiological, 
hepatobiliary and urinary tract effects, as well as 
developmental, genetic, neurotoxic, reproductive toxicity, 
and carcinogenicity. 
(M)CASE Ultra & 
modules
148
 
QSAR hybrid 
approach 
LB, 2D ~450 models 
covering a wide 
range of toxicological 
and pharmacological 
measures 
commercial Uses a fragment-based approach and continuous 
parameters for modelling toxicity. 
ToxTree
149
 decision tree LB, 2D 17 modules for 
predicting 
toxicological and 
metabolic properties 
free, open source Free software for predicting various toxicological 
properties. 
TOPKAT
150
 linear regression 
(different types) 
LB, 2D 14 toxicity measures commercial Predicts toxicity measures in a variety of in vitro assays 
and animal models. 
Percepta Toxicity 
modules
132
 
PLS (GALAS) LB, 2D 7 models for a variety 
of toxicity measures 
commercial Prediction of acute toxicity, aquatic toxicity, endocrine 
disruption, genotoxicity, hERG channel inhibition, 
irritation and health effects. 
ADMET Predictor
131
 ANN ensemble LB, 2D 
and 3D 
19 models for a 
variety of toxicity 
and environmental 
commercial Prediction of endocrine disruption, hERG channel 
inhibition, skin sensitization, phospholipidosis etc. 
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fate measures 
TIMES
137
 collection of 
QSAR models 
LB, 2D 15 models for a 
variety of toxicity 
endpoints 
commercial Collection of models for evaluating the toxicity of 
metabolites, including skin sensitization, acute oral 
toxicity, phototoxicity, various endpoints related to 
endocrine disruption and cancerogenicity. 
SYMMETRY
151
 collection of 
QSAR models 
LB >80 models for a 
variety of toxicity 
endpoints 
commercial Collection of models for preclinical and clinical predictive 
toxicology. 
a
Adapted with permission from 
43
. Copyright 2012 American Chemical Society. Supplemented with data from 
34
, revised, and extended 
with additional software categories and products.
 
b
Abbreviations: ADME, absorption, distribution, metabolism, excretion; ANN, artificial neural network; DFT, density functional theory; 
LB, ligand-based; MLR, multiple linear regression; PLS, partial least squares; SB, structure-based; SoM, site of metabolism; SVM, support 
vector machine. 
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Table 3. Scope and Limitations of Computational Methods. 
Investigation/prediction 
of 
Computational method(s) Scope, limitations 
Structure, function and 
mechanisms of metabolic 
enzymes 
Homology modelling, quantum 
mechanics, molecular dynamics 
simulations etc. 
Analysis of ligand binding events and enzyme mechanisms at a high level of detail and accuracy. 
Particularly useful for the investigation of unstable reaction intermediates with very short 
lifetimes. 
Sites of metabolism Knowledge-based systems, data mining, 
machine learning, QSAR models, 
reactivity models, ligand docking, 
molecular interaction fields, shape-based 
methods etc. 
Able to predict the likely SoMs with adequate accuracy: In general at least one SoM is correctly 
identified among the three highest-ranked atom positions of a molecule in 70-90% of all cases
152
 
within the domain of chemical applicability. 
Metabolites (chemical 
structure) 
Knowledge-based systems, data mining Dominated by knowledge-based systems. Can produce large numbers of metabolites. Main 
challenge: finding ways of ranking metabolites accurately. 
Metabolic rates Quantum mechanics, molecular 
dynamics simulations, (QSAR models) 
Prediction generally not possible. Only within extremely narrow chemical space QSAR-like 
approaches may work. 
Interactions of drugs 
with targets related to 
drug metabolism 
QSAR models Prediction of ligand affinity and inhibitory activity where adequate training data is available. 
Prediction of mechanism-based inhibitors remains highly challenging. 
Free energy calculations Accurate prediction of binding affinities without need for extensive training data. 
Computationally expensive and labour-intense. 
Bioactivity and 
toxicological effects 
Various ligand- and structure-based 
approaches 
Target prediction methods have become abundantly available but high false positives rates (i.e. 
accurate ranking of targets) remain a limiting factor. Prediction of bioactivities for metabolites 
hampered by lack of training data. Rule-based approaches are able to detect most toxicophores, 
but prediction of time-dependent inhibitors remains challenging. 
Metabolite identification 
(MetID) 
Various metabolite generation and 
spectra analysis approaches 
Has seen major advances in recent years, driven by increasingly available data, data exchange and 
new algorithms. Major scientific instruments manufacturers offer bespoke MetID software. 
Vendor-independent and open-source packages are becoming increasingly available. 
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Table 4. Examples of Data Resources for Drug Metabolism and Overview of Their Information 
Content. 
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ADME Database
153
 Database of interactions of small 
molecules with drug-metabolising 
enzymes and transporters. 
>100,000 protein-ligand 
interactions 
x x   x x x x    
BindingDB
154
 Bioactivity database focused on 
drug targets. 
>1,000,000 bioactivities for 
>450,000 compounds 
x x x x x x x x    
ChEMBL
155
 Very large repository for 
bioactivity data. 
>12,000,000 bioactivities for 
>1,600,000 compounds 
x x x  x  x x    
Drug Database (GOSTAR)
156
 Comprehensive resource for 
metabolites of approved drugs. 
PK parameters collected from 
>50,000 publications. 
x x x x x x  x x   
DrugBank
157
 Comprehensive encyclopaedic 
database on drugs. 
>1,500 approved drugs 
>1,200 drug metabolites 
x x x x x x x x x  x 
EAWAG-BBD
158
 Data resource for biodegradation 
of xenobiotics, mainly 
environmental pollutants. 
~1,400 molecules 
>1,500 reactions 
>200 degradation pathways 
(x) x x x x       
Human Metabolome Database 
(HMDB)
159
 
Database focused on human 
endogenous metabolites. 
>41,000 metabolites  x x x x x x  x  x 
KEGG
160
 Large database comprising ~20 
different (sub-) collections of data 
>17,000 molecules (KEGG 
COMPOUND) 
x x x x x  x x x   
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on metabolism. 
MetaBase
161
 Database of biological properties 
and effects of drugs and drug-like 
molecules. 
>9,000 metabolic reactions 
>5,000 endogenous metabolites 
x x x x x   x x   
Metabolism and Transport Drug 
Interaction Database (DIDB)
162
 
Collection of in vitro and in vivo 
data on drug-drug interactions in 
humans. 
Data from >8,300 publications 
>70 new drug applications 
x x    x x  x   
Metabolite
163
 Collection of metabolic pathways 
of drugs, drug-like molecules, 
natural products, and endogenous 
metabolites. 
>100,000 biotransformations 
~15,000 metabolic pathways 
x x x x x    x   
METLIN
164
 Large and quickly expanding 
repository of metabolite 
information and MS/MS spectra. 
Powerful online search. 
>240,000 metabolites 
>60,000 MS/MS spectra 
x x x        x 
PharmGKB
165
 Encyclopaedia focused on drugs. 
Rich in pharmacogenomics data. 
>3,000 drugs 
>100 drug metabolism 
pathways 
x x x x x x x x x   
PKKB
166
 Pharmacokinetic data for drugs. >1,600 drugs 
>11,000 data points 
x x x x x x  x x   
Protein Data Bank (PDB)
167
 Largest public repository for 
experimentally determined 
structures of biomolecules 
> 100,000 structures x x   x  x x  x  
PubChem
168
 One of the largest libraries of 
chemicals. Extensive 
pharmacological data for drug 
molecules. 
>52,000,000 molecules x x x x x x x x x   
SuperCyp
169
 Database for drug-CYP 
interaction. Contains biological 
and structural data, and 
information on CYP 
polymorphisms. 
>1,100 drugs 
>2,700 drug-CYP interactions 
x x   x  x     
Wikipedia
170
 Largest and most popular general 
encyclopaedia. 
Comprehensive coverage of 
marketed drugs, drug candidates 
and failed drugs. 
x x x x x x x x x   
 
